MariMed Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting third-quarter revenue of $44,227 thousand and a pre-tax loss of $744 thousand.

Key Highlights

  • Revenue growth: MariMed reported revenue of $44,227 thousand for the three months ended September 30, 2026, up from $40,764 thousand in the same period of 2025.
  • Nine-month revenue: Revenue for the nine months ended September 30, 2026 was $125,633 thousand, compared to $118,176 thousand for the nine months ended September 30, 2025.
  • Pre-tax loss: The company reported a loss before income taxes of $744 thousand for Q3 2026, compared to a loss of $182 thousand in Q3 2025.
  • Accumulated deficit: The accumulated deficit stood at $138,811 thousand as of September 30, 2026, up from $127,932 thousand at December 31, 2025.
  • Total assets: Total assets were $198,313 thousand at September 30, 2026, compared to $202,565 thousand at December 31, 2025.
  • Income taxes payable: Income taxes payable increased to $34,221 thousand at September 30, 2026, from $26,981 thousand at December 31, 2025.
  • Shares outstanding: As of November 10, 2026, 405,996,010 shares of common stock were outstanding.

MariMed Q3 2026 Financial Results: Revenue Up, Losses Deepen

According to the filing, MariMed Inc. generated revenue of $44,227 thousand in the three months ended September 30, 2026, an increase from $40,764 thousand in the comparable prior-year quarter. Cost of revenue for Q3 2026 was $27,067 thousand, yielding a gross profit of $17,160 thousand, compared to a gross profit of $16,363 thousand in Q3 2025. Income from operations for the quarter was $1,221 thousand, down from $1,599 thousand in the year-earlier period.

The filing disclosed that total operating expenses for Q3 2026 were $15,939 thousand, driven by personnel costs of $7,942 thousand, general and administrative expenses of $6,709 thousand, and marketing and promotion costs of $1,056 thousand. Interest expense of $2,003 thousand contributed to a total net interest and other expense of $1,965 thousand for the quarter, resulting in a pre-tax loss of $744 thousand. For the nine-month period, the company reported a loss before income taxes of $3,413 thousand, compared to $3,534 thousand in the nine months ended September 30, 2025.

On the balance sheet, the company reported total assets of $198,313 thousand and total liabilities of $151,326 thousand as of September 30, 2026. Mortgages and notes payable, net of current portion, stood at $75,032 thousand, up from $70,192 thousand at December 31, 2025. The company also disclosed a change in its preferred stock structure: the original Series B convertible preferred stock, with 4,908,333 shares authorized, issued, and outstanding at December 31, 2025, carried zero shares at September 30, 2026, replaced by a New Series B convertible preferred stock with 26,900,000 shares authorized, issued, and outstanding, carrying a carrying value of $6,933 thousand. The filing notes that the company's forward-looking statements are subject to risks and uncertainties and are the company's own characterizations.

What Was Disclosed

MariMed Inc. filed a quarterly report covering the period ended September 30, 2026, disclosing revenue of $44,227 thousand, a pre-tax loss of $744 thousand, total assets of $198,313 thousand, and 405,996,010 shares of common stock outstanding as of November 10, 2026.